[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587857":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":31,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Barnet Dulaney Perkins Eye Centers","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment naïve (including medication in either eye, previous laser or surgery) mild to moderate POA",null,"(including medication in either eye, previous laser or surgery) mild to moderate POA",[13],"Device: DSLT enables newly diagnosed patients to remain well controlled and off medications",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":10},"DEVICE","DSLT enables newly diagnosed patients to remain well controlled and off medications",[9],[20],{"name":21,"affiliation":5,"role":22},"Christine Funke, Medical Doctor","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Derek J Arnson, Master of Education","CONTACT","4804201005","derek.arnson@researchavp.com",{"name":21,"role":26,"phone":27,"phoneExt":10,"email":30},"christine.funke@BDPEC.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Mesa","Arizona","85206","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-111.82264,33.42227,{"lat":43,"lon":42},[46,47,48],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":21,"role":26,"phone":27,"phoneExt":10,"email":30},{"name":21,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52],{"name":53,"class":54},"Alcon, a Novartis Company","INDUSTRY","100587857","dslt-performance-in-treatment-nave-patients-with-newly-diagnosed-open-angle-glaucoma-100587857",false,"NCT06933836","DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma","How Does First Line Treatment With DSLT Perform in Treatment-naïve Patients With Newly Diagnosed Primary Open Angle Glaucoma","Inclusion Criteria:\n\n* Primary open angle glaucoma\n* Patients age 30 or greater with an IOP of 18-26 mmHg\n* Mild to moderate POAG patients (mild or moderate according to the AAO PPP Guidelines)\n* DSLT procedure\n\nExclusion Criteria:\n\n* History of prior glaucoma treatment - this includes past medication use (in either eye), previous lasers or incisional surgery\n* Angle closure patients\n* Ocular Hypertension\n* Baseline VF MD of worse than -12dB\n* Uncontrolled systemic microvascular disease (eg. HTN, DM)\n* Subjects with peri-limbal findings (e.g. melanosis, tumors, extensive pterygium, significant senile arcus and pterygium)","ALL","30 Years",{"count":65,"type":66},55,"ESTIMATED","OBSERVATIONAL","DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.",[70],"Open Angle Glaucoma (OAG)",[72,73,74],"Glaucoma","DSLT","Interocular Pressure","2025-04-16",{"date":77,"type":78},"2025-04-18","ACTUAL",{"date":80,"type":78},"2025-03-31",{"date":82,"type":66},"2027-12-31",{"name":5,"class":6},1]